drugset / Trial / NCT00171184

Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder

NCT00171184

Phase 4 Completed 400 enrolled Novartis Procter and Gamble · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to assess the efficacy, safety and tolerability of 12-weeks treatment with darifenacin in patients aged \>Ý 65 years with OAB.

Timeline

Start
2005-04
Primary completion
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Darifenacin Small molecule 7.5 mg
Subject Darifenacin Small molecule 15 mg

Indications